Generic Name and Formulations:
Temazepam 7.5mg, 15mg, 22.5mg, 30mg; caps.
Indications for RESTORIL:
Short-term (7–10 days) treatment of insomnia.
Use lowest effective dose. Usual dose: 7.5mg–30mg at bedtime. Elderly or debilitated: initially 7.5mg. Max 1 month/℞.
<18yrs: not established.
Risks from concomitant use with opioids.
Risks from concomitant use with opioids (see Interactions). Suicidal tendencies. Depression. Pulmonary, renal, or hepatic impairment. Drug or alcohol abuse. Reevaluate if used ≥2 weeks. Sleep disturbances after stopping drug. Avoid abrupt cessation after prolonged use. Elderly. Nursing mothers.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants.
Drowsiness, headache, fatigue, nervousness, lethargy, dizziness, hangover, confusion, weakness, paradoxical excitement, euphoria; sleep-driving and other complex behaviors (eg, preparing/eating food), anaphylaxis, angioedema.
Caps 7.5mg—30, 100; 22.5mg—30; 15mg, 30mg—100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline